Literature DB >> 24786438

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Kaberi Dasgupta1, Robert R Quinn2, Kelly B Zarnke3, Doreen M Rabi4, Pietro Ravani2, Stella S Daskalopoulou5, Simon W Rabkin6, Luc Trudeau7, Ross D Feldman8, Lyne Cloutier9, Ally Prebtani10, Robert J Herman11, Simon L Bacon12, Richard E Gilbert13, Marcel Ruzicka14, Donald W McKay15, Tavis S Campbell16, Steven Grover17, George Honos18, Ernesto L Schiffrin19, Peter Bolli20, Thomas W Wilson21, Patrice Lindsay22, Michael D Hill23, Shelagh B Coutts24, Gord Gubitz25, Mark Gelfer26, Michel Vallée27, G V Ramesh Prasad28, Marcel Lebel29, Donna McLean30, J Malcolm O Arnold8, Gordon W Moe31, Jonathan G Howlett32, Jean-Martin Boulanger33, Pierre Larochelle34, Lawrence A Leiter35, Charlotte Jones36, Richard I Ogilvie37, Vincent Woo38, Janusz Kaczorowski39, Kevin D Burns40, Robert J Petrella41, Swapnil Hiremath42, Alain Milot43, James A Stone44, Denis Drouin45, Kim L Lavoie46, Maxime Lamarre-Cliche47, Guy Tremblay48, Pavel Hamet49, George Fodor50, S George Carruthers51, George B Pylypchuk21, Ellen Burgess52, Richard Lewanczuk30, George K Dresser53, S Brian Penner54, Robert A Hegele55, Philip A McFarlane56, Milan Khara57, Andrew Pipe58, Paul Oh59, Peter Selby60, Mukul Sharma61, Debra J Reid62, Sheldon W Tobe63, Raj S Padwal64, Luc Poirier65.   

Abstract

Herein, updated evidence-based recommendations for the diagnosis, assessment, prevention, and treatment of hypertension in Canadian adults are detailed. For 2014, 3 existing recommendations were modified and 2 new recommendations were added. The following recommendations were modified: (1) the recommended sodium intake threshold was changed from ≤ 1500 mg (3.75 g of salt) to approximately 2000 mg (5 g of salt) per day; (2) a pharmacotherapy treatment initiation systolic blood pressure threshold of ≥ 160 mm Hg was added in very elderly (age ≥ 80 years) patients who do not have diabetes or target organ damage (systolic blood pressure target in this population remains at < 150 mm Hg); and (3) the target population recommended to receive low-dose acetylsalicylic acid therapy for primary prevention was narrowed from all patients with controlled hypertension to only those ≥ 50 years of age. The 2 new recommendations are: (1) advice to be cautious when lowering systolic blood pressure to target levels in patients with established coronary artery disease if diastolic blood pressure is ≤ 60 mm Hg because of concerns that myocardial ischemia might be exacerbated; and (2) the addition of glycated hemoglobin (A1c) in the diagnostic work-up of patients with newly diagnosed hypertension. The rationale for these recommendation changes is discussed. In addition, emerging data on blood pressure targets in stroke patients are discussed; these data did not lead to recommendation changes at this time. The Canadian Hypertension Education Program recommendations will continue to be updated annually.
Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24786438     DOI: 10.1016/j.cjca.2014.02.002

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  91 in total

Review 1.  Recognition and Management of Hypertension in Older Persons: Focus on African Americans.

Authors:  Carolyn H Still; Keith C Ferdinand; Gbenga Ogedegbe; Jackson T Wright
Journal:  J Am Geriatr Soc       Date:  2015-10       Impact factor: 5.562

2.  Systolic BP and Mortality in Older Adults with CKD.

Authors:  Jessica W Weiss; Dawn Peters; Xiuhai Yang; Amanda Petrik; David H Smith; Eric S Johnson; Micah L Thorp; Cynthia Morris; Ann M O'Hare
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-14       Impact factor: 8.237

3.  Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults for pharmacists: An update.

Authors:  Sarah A Lamb; Yazid N Al Hamarneh; Sherilyn K D Houle; Alexander A Leung; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2017-11-29

4.  Dietary Approach to Stop Hypertension with Sodium Reduction for Chinese Canadians (DASHNa-CC): A Pilot Randomized Controlled Trial.

Authors:  P Zou; C-L Dennis; R Lee; M Parry
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

5.  Different strategies from monotherapies to dual or triple fixed dose combination therapies to achieve blood pressure goals: a summary of a satellite symposium from the European Society of Hypertension, June 13-16, 2014 Athens, Greece. Introduction.

Authors:  Josep Redon
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-07

6.  Resistance to recommending exercise in hypertension?

Authors:  J B Byrd
Journal:  J Hum Hypertens       Date:  2014-11-13       Impact factor: 3.012

7.  Prevalence and predictors of resistance and aerobic exercise among hypertensive adults in the United States.

Authors:  L Mu; A J Cohen; K J Mukamal
Journal:  J Hum Hypertens       Date:  2014-11-13       Impact factor: 3.012

8.  Sex and gender considerations in Canadian clinical practice guidelines: a systematic review.

Authors:  Cara Tannenbaum; Barbara Clow; Margaret Haworth-Brockman; Patrice Voss
Journal:  CMAJ Open       Date:  2017-02-10

Review 9.  Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High-Income Countries: A Systematic Review.

Authors:  Mayowa Owolabi; Paul Olowoyo; J Jaime Miranda; Rufus Akinyemi; Wuwei Feng; Joseph Yaria; Tomiwa Makanjuola; Sanni Yaya; Janusz Kaczorowski; Lehana Thabane; Josefien Van Olmen; Prashant Mathur; Clara Chow; Andre Kengne; Raelle Saulson; Amanda G Thrift; Rohina Joshi; Gerald S Bloomfield; Mulugeta Gebregziabher; Gary Parker; Charles Agyemang; Pietro Amedeo Modesti; Shane Norris; Luqman Ogunjimi; Temitope Farombi; Ezinne Sylvia Melikam; Ezinne Uvere; Babatunde Salako; Bruce Ovbiagele
Journal:  Hypertension       Date:  2016-10-03       Impact factor: 10.190

Review 10.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.